Theriva Biologics Inc

Theriva Biologics Inc has a market capitalization of $14.73 million and a price-to-book ratio of 0.53, indicating that the company is trading at a significant discount to its book value. The company's liquidity position is strong, with $16.59 million in cash and equivalents, and a current ratio of 2.88, suggesting it can easily cover its short-term liabilities. However, the company has a negative return on equity of -30.08% and a negative return on assets of -19.62%, indicating poor profitability and asset utilization. The company's operating income and net income are both negative, at -$8.49 million and -$8.32 million, respectively, reflecting ongoing losses. The company's debt-to-equity ratio is 0.01, indicating a very low level of leverage and minimal financial risk. Despite this, the company's free cash flow is negative at -$8.28 million, suggesting that it is not generating sufficient cash from operations to fund its activities. Theriva Biologics Inc does not disclose specific segments or geographic regions in its financial reporting, making it difficult to assess revenue concentration or geographic exposure. The company's capital expenditure is minimal at -$1,000, indicating that it is not investing heavily in new assets. The company's growth trajectory is uncertain, as it has not provided specific revenue growth projections for the current or next fiscal year. The company's risk assessment indicates low liquidity and dilution risks, with no immediate filing-based liquidity or dilution flags detected. The company's dilution potential is also low, and no adjustments have been applied to its valuation metrics. The company's recent financial filings do not indicate any significant events that would impact its operations or financial position.